Tcell

Altogether, 16 consecutive patients with MF/SS (MF 10, SS 6) received an alloHCT after TBI/fludarabine-based conditioning as institutional treatment standard between April 2014 and February 2025. Median age at transplantation …

A 21-year-old patient with aggressive lymphoma sought care at Cleveland Clinic Cancer Institute after rapid acceleration of her disease. Caring for a young patient with lymphoma and swift progression to …

Bangham CRM. HTLV-1 persistence and the oncogenesis of adult T-cell leukemia/lymphoma. Blood. 2023;141:2299–2306. Google Scholar Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. …

NatureReal-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphomaPrior to the advent of chimeric antigen receptor (CAR) T-cell therapy, patients with relapsed/refractory (R/R) mantle cell …

Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre …

Competing interests HT received honoraria from AstraZeneca plc, Bristol Myers Squibb, Chugai Pharma, Janssen, Kyowa Kirin, Meiji Seika Pharma, Nippon Shinyaku, Mundipharma, Ono Pharmaceutical, SymBio pharmaceuticals, Takeda Pharmaceutical, Eisai, Fujimoto …